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Abstract: Mitochondrial dysfunction and iron (Fe) dyshomeostasis are invoked among the mechanisms
contributing to muscle aging, possibly via a detrimental mitochondrial–iron feed-forward loop.
We quantified the labile Fe pool, Fe isotopes, and the expression of mitochondrial Fe handling proteins in
muscle biopsies obtained from young and older adults. The expression of key proteins of mitochondrial
quality control (MQC) and the abundance of the mitochondrial DNA common deletion (mtDNA4977)
were also assessed. An inverse association was found between total Fe and the heavier Fe isotope (56Fe),
indicating an increase in labile Fe abundance in cells with greater Fe content. The highest levels of
labile Fe were detected in old participants with a Short Physical Performance Battery (SPPB) score ≤ 7
(low-functioning, LF). Protein levels of mitoferrin and frataxin were, respectively, higher and lower in
the LF group relative to young participants and older adults with SPPB scores ≥ 11 (high-functioning,
HF). The mtDNA4977 relative abundance was greater in old than in young participants, regardless of
SPPB category. Higher protein levels of Pink1 were detected in LF participants compared with young
and HF groups. Finally, the ratio between lipidated and non-lipidated microtubule-associated protein
1A/1B-light chain 3 (i.e., LC3B II/I), as well as p62 protein expression was lower in old participants
regardless of SPPB scores. Our findings indicate that cellular and mitochondrial Fe homeostasis is
perturbed in the aged muscle (especially in LF older adults), as reflected by altered levels of mitoferrin
and frataxin, which, together with MQC derangements, might contribute to loss of mtDNA stability.
Keywords: autophagy; iron dyshomeostasis; iron metabolism; iron isotopes; mitochondria;
mitochondrial quality control; mitophagy; muscle aging; oxidative stress; physical performance
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1. Introduction
The preservation of mobility and functional independence in older adults has become a clinical
and public health priority, as well as a major goal of the National Institute on Aging and the National
Institutes of Health strategic plan for research on aging [1]. Our work and that of others have shown
that low-functioning (LF) older adults have a more rapid functional decline compared with those
who are high-functioning (HF) [2–7]. Habitual walking speed and performance on standard measures
of physical function can be considered a composite measure of healthy aging and predict mobility
disability and all-cause mortality [3–7]. However, the biological mechanisms underlying the accelerated
functional loss in LF older adults remain poorly understood, and few strategies are currently available
to prevent this decline.
Mitochondrial dysfunction in skeletal muscle is invoked as a major factor underlying the onset
and progression of functional decline during aging [8–11]. Yet, the molecular determinants underlying
mitochondrial dysfunction in muscle and the associated functional decline are presently unclear.
Notwithstanding, alterations in mitochondrial iron (Fe) handling in skeletal myocytes have been
proposed as a mechanism leading to organelle dysfunction and muscle atrophy [12]. Indeed, variants
in genes involved in the regulation of Fe handling were found to be associated with healthspan and
physical performance in older adults [13,14].
The majority of body Fe is sequestered as heme Fe into functional biomolecules, including
hemoglobin, myoglobin, cytochromes, and heme thiolates [15]. A smaller fraction of non-heme Fe
exists as metallic ion serving as an enzyme cofactor or bound to cytosolic ferritin and hemosiderin to
form Fe reserves [15]. Non-heme Fe is also an integral part of transferrin and is core to mitochondrial
electron transport chain (ETC) complexes within Fe-sulfur clusters (ISCs) [16,17]. Of all non-heme Fe,
approximately 5% exists as a chelatable Fe fraction and feeds a labile Fe pool. The biological relevance
of this fraction resides in its chemistry involving ferrous (Fe2+) and ferric (Fe3+) ions. Fe2+ participates
in Fenton reactions and produce highly reactive radicals, holding the potential of generating protein,
lipid and nucleic acid oxidative adducts which are detrimental to the cell [18,19]. The reduction of
Fe3+ to Fe2+ in the human body is accompanied by Fe isotope fractionation resulting in enrichment of
the lighter isotope (54Fe) in the reduced Fe fraction [20,21]. Therefore, the isotope composition of the
cellular Fe pool may represent a “surrogate” indicator of the cell’s redox status.
The redistribution of non-heme Fe across tissues is regulated by the defensin-like hormone
hepcidin via binding and subsequent degradation of the Fe export protein ferroportin [22,23]. Cellular
Fe import, instead, occurs via a transferrin receptor (TfR) and is highly responsive to intracellular Fe
levels. The two mitochondrial proteins, mitoferrin and frataxin, also participate in intracellular Fe
handling. Mitoferrin, which is located at the inner mitochondrial membrane, regulates mitochondrial
Fe import, while frataxin is pivotal for mitochondrial Fe storage. Studies in preclinical models have
established that frataxin is also involved in heme biosynthesis, ISC cluster assembly, and aconitase
repair [24,25]. Frataxin deficiency in humans results in mitochondrial Fe overload and Friedreich’s
ataxia, a major inheritable neurodegenerative disorder [26].
The skeletal muscle is the major bodily reservoir of non-heme Fe. The latter accumulates in
muscles with aging, which has been linked to oxidative damage to biomolecules and organelles,
including mitochondria [27–31]. As such, age-related mitochondrial dysfunction and Fe dyshomeostasis
are advocated among the biological mechanisms involved in the pathogenesis of sarcopenia [12].
The existence of a mitochondrial–Fe feed-forward loop in the aging muscle has been hypothesized.
This loop would involve perturbations in cellular Fe transport leading to Fe accrual, oxidative damage to
mitochondrial DNA (mtDNA) and ETC complexes, together impinging on mitochondrial function and
eventually generating a vicious circle that promotes further Fe overload and oxidative stress [12,32–34].
In light of the vital functions of mitochondria, the maintenance of organellar structural and
functional integrity is essential for cell’s homeostasis and is ensured by an integrated network of
pathways (i.e., mitochondrial dynamics, mitophagy, biogenesis, and proteostasis), collectively termed
mitochondrial quality control (MQC) [35–37]. The MQC axis becomes impaired during aging, which is
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thought to trigger and amplify mitochondrial dysfunction [37,38]. As a result, pro-inflammatory routes
may be triggered to dispose dysfunctional organelles [39–44].
In a recent work by our group, we provided an initial appraisal of the relationship between
Fe imbalance, mitochondrial damage in muscle, and chronic inflammation in a cohort of older
adults [32]. In that study, we observed that Fe import via TfR, a main Fe import protein, was markedly
decreased in muscles of older people. Moreover, an association between Fe dyshomeostasis and
systemic inflammation—i.e., higher circulating levels of hepcidin, interleukin 6, and C-reactive
protein—emerged as a relevant factor possibly contributing to physical function impairment [32].
In subsequent work detailed in this manuscript, we further explored the relationship between Fe
imbalance and mitochondrial dyshomeostasis in muscle biopsies obtained from the same cohort of
individuals. Specifically, we sought to determine whether a differential distribution of Fe isotopes
within the labile Fe pool and changes in the expression of proteins involved in mitochondrial Fe
handling (i.e., mitoferrin and frataxin) and MQC in muscle would be associated with aging and
declining physical performance.
2. Materials and Methods
2.1. Participants
Physically inactive community-dwelling men and women aged 70 years and older or between
the ages of 18 and 35 years were included in the study. The Recruitment Core of the University of
Florida Claude D. Pepper Older Americans Independence Center coordinated participants enrolment,
as previously described [11,45,46]. A set of eligibility criteria, common for the two age groups,
was chosen to minimize the possible confounding effect of comorbidities, medications, and lifestyle
habits on the relationship among physical performance, Fe metabolism, and measures of muscle
mitochondrial quality, as detailed elsewhere [32,47].
Older adults were categorized in HF and LF according to the summary score obtained on the
Short Physical Performance Battery (SPPB) [48]. In particular, participants with an SPPB score ≥ 11
were classified as HF, while those who scored ≤ 7 were categorized as LF. The cut-off values
were chosen for their ability to predict relevant health outcomes in older adults (e.g., functional
limitations, institutionalization, mortality) [48–52]. To allow greater discrimination in physical function
and biochemical parameters between the two groups, participants scoring 8–10 on the SPPB were
not included.
The study protocol was approved by the University of Florida’s Institutional Review Board
(IRB201300790) and all participants provided written informed consent prior to enrolment.
2.2. Collection of Muscle Biopsies
Muscle biopsies were obtained from the vastus lateralis of the dominant leg by percutaneous
needle biopsy, under local anesthesia [46]. Upon collection, muscle specimens were cleaned of any
visible blood and fat, snap-frozen in liquid nitrogen and stored at −80 ◦C until further processing
and analysis.
2.3. Measurement of Iron Isotopes in Muscle Biopsies by Inductively Coupled Plasma-Mass Spectrometry
All reagents used for the sample preparation and Fe ion-exchange purification were Optima-grade
and the work was performed under Clean Lab (class 1000) environment. Between 0.013 g and 0.029 g
of muscle tissue were digested for the determination of Fe concentration, following methods described
elsewhere [32]. Briefly, tissues were digested in concentrated nitric acid (HNO3) and 30% hydrogen
peroxide (H2O2) in pre-cleaned Teflon vials. A small fraction of the final solution was used for the
determination of Fe concentration in muscle samples [32]. The remaining digested muscle solution
was evaporated to dryness and converted to chlorides by 3× evaporation with 7 N hydrochloric acid
(HCl). Fe was purified on an AG® MP-1M resin (Bio-Rad Laboratories, Hercules, CA, USA) following
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methods described by Maréchal et al. [53]. Ion-exchange columns were packed with 2 mL of AG®
MP-1M (100–200 mesh) resin. After packing, the columns were washed with 0.5 N HNO3, followed by
milliQ water, then 1 N HCl again followed by milliQ water. After the washing steps, the columns were
equilibrated with 4 mL 7 N HCl. Samples were loaded in 7 N HCl with 0.001% H2O2. The matrix was
eluted with 23 mL of 7 N HCl and Fe was collected in 10 mL 1 N HCl. The Fe fraction was evaporated to
dryness. After evaporation, 0.5 mL of 8 N HNO3 were added to the dry residue and evaporated again.
The samples were subsequently dissolved in 2% HNO3 for Fe isotope measurements. The Fe yield after
column purification was 101% (±3%). Fe isotope measurements were performed on a Nu-Plasma 3
MC-ICP-MS (AMETEK, Wrexham, UK) in the high-resolution mode. Due to the low total Fe available,
samples were introduced in the MC-ICP-MS via an Aridus3 desolvating nebulizer system (Teledyne
CETAC, Omaha, NE, USA). All samples and standards were adjusted to 500 ppb Fe in the final solution,
which resulted in around 6.5 V signal for 56Fe. Fe isotope measurements were performed on Faraday
detectors in standard–sample–standard mode with IRM014 used as the bracketing standard. Fe isotope
data are presented in delta-notation (δ) in parts per thousand (%) using the following equation [20]:
δ56Fe = (56Fe/54Fe(sample)/56Fe/54Fe(IRM014)) × 1000 (1)
δ57Fe was calculated with Equation (1) using 57Fe/54Fe ratio instead of 56Fe/54Fe. Fe isotopes
measured in BCR2 standard (n = 7), prepared and analyzed together with the samples, yielded
the following results: δ56Fe = 0.097 (±0.014) and δ57Fe = 0.163 (±0.048). These values are within
the error of published data for BCR2 by Craddock and Dauphas [54]: δ56Fe = 0.091 (±0.011) and
δ57Fe = 0.126 (±0.017).
2.4. Western Immunoblotting
Protein lysates were prepared from muscle biopsies and levels of beclin, microtubule-associated
protein 1A/1B-light chain 3 (LC3B) I and II, frataxin, mitoferrin, sequestosome 1 (SQSTM1)/p62,
Parkin, and phosphatase and tensin homolog-induced kinase 1 (Pink1) were measured by Western
immunoblotting, as previously described [11]. A total of 50 µg of protein was separated on 4–20%
polyacrylamide gels (Bio-Rad Laboratories), transferred onto polyvinylidene difluoride membranes
(Bio-Rad Laboratories), and blocked for 1 h in 2.5% or 5% milk in Tris-buffered saline with Tween 20
(Bio-Rad Laboratories), as appropriate (Table 1). Bovine serum albumin- and milk-blocked blots were
probed with commercially available primary and secondary antibodies listed in Table 1. Protein bands
were detected with SuperSignal West Femto Maximum Sensitivity Substrate (Thermo Fisher Scientific,
Waltham, MA, USA) using a ChemiDoc XRS imager (Bio-Rad Laboratories) and target bands were
quantified using the Image Lab 6.0 software (Bio-Rad Laboratories). The “Total Lane Protein” setting
was used for the quantification of target proteins. The spot density of each band was normalized to
the total protein amount loaded in the same lane, as determined by the densitometric analysis of the
corresponding Ponceau S-stained membranes [55,56].
Cells 2020, 9, 2579 5 of 16
Table 1. Technical specifications of the primary antibodies used for Western immunoblotting.







Polyclonal Rabbit 1:2000 5% BSATBS-t 60
Frataxin Abcam (Cambridge,MA, USA) (ab110328) Monoclonal Mouse 1:500
5% milk
TBS-t 23





Mitoferrin Abcam (ab102959) Polyclonal Rabbit 1:1000 5% milkTBS-t 37
SQSTM1/p62 Cell SignalingTechnology (#5114S) Polyclonal Rabbit 1:2000
5% BSA
TBS-t 62
Parkin Abcam (ab77924) Monoclonal Mouse 2 µg/mL 2.5% milkTBS-t 52
Pink1 Abcam (ab23707) Polyclonal Rabbit 1:1000 5% milkTBS-t 66
Abbreviations: BSA, bovine serum abumin; LC3B, microtubule-associated protein 1A/1B-light chain 3; Pink1,
phosphatase and tensin homolog-induced kinase 1; SQSTM1/p62, sequestosome 1/p62; TBS-t, Tris-buffered saline
with Tween 20.
2.5. Quantification of Mitochondrial DNA Deletion
Quantitative real-time polymerase chain reaction (qRT–PCR) was used to determine muscle
levels of the mtDNA common deletion of 4977 bp (mtDNA4977) in total DNA purified as
described elsewhere [57–62]. DNA purification was performed using a Wizard Genomic DNA
Purification Kit (Promega, Madison, WI, USA) according to the manufacturer’s instructions.
Briefly, 10–20 mg of muscle tissue were homogenized in 1 mL of nuclei cell lysis solution with
a hard tissue disposable probe (Omni international, Kennesaw, GA, USA) on a PowerGen 500
homogenator (Thermo Fisher Scientific). DNA quantification was performed on a NanoDrop
1000 spectrophotometer (Thermo Fisher Scientific) and nucleic acid integrity was verified by gel
electrophoresis on 0.8% agarose gel in 1× TBE (90 mM Tris-borate pH 7.4, 90 mM boric acid, 2.5 mM
ethylenediaminetetraacetic acid). Forward and reverse primers for the assessment of mtDNA4977 were
designed to span both ends of the deletion (forward 5′-CCTTACACTATTCCTCATCACC-3′; reverse
5′-TGTGGTCTTTGGAGTAGAAACC-3′; amplicon length: 127 bp) [62]. Primer pairs were checked
for their specificity of binding to the mitochondrial genome by verifying the lack of cross-binding
to nuclear-mtDNA sequences (numts) and by running melting curve analysis, non-template control
reactions, and gel electrophoresis of PCR products. Glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) was used as an internal control (forward 5′-CAGAACATCATCCCTGCCTCTAC-3′; reverse
5′-TTGAAGTCAGAGGAGACCACCTG-3′; amplicon length 251 bp). Each sample was analyzed in
triplicate in 20 µL final volume. The reaction mixture consisted of 1× Terra qPCR Direct SYBR Premix
(Takara Bio USA Inc., Mountain View, CA, USA), 0.2 µM forward and reverse primers, and 10 ng of
total DNA template. The amplification proceeded for 40 cycles. Amplification reactions were run
on a CFX96 Touch™ Real-Time PCR Detection System (Bio-Rad Laboratories). The abundance of the
mtDNA4977 deletion was calculated according to the Pfaffl mathematical model using the formula
R = 2∆∆Ct [63] and normalized to the relative mtDNA content. MtDNA relative quantification was
obtained by RT–PCR using the Human Mitochondrial DNA Monitoring Primer Kit (Takara Bio USA).
The primers amplified mitochondrial genes corresponding to the nicotinamide adenine dinucleotide
reduced form (NADH) dehydrogenase subunits 1 and 5 (ND1, ND5) and nuclear genes corresponding
to solute carrier organic anion transporter family, member 2b1 (SLCO2B1), and serpin family A member
1 (SERPINA1) [32]. Differences in threshold cycle values for the ND1/SLCO2B1 pair (∆Ct1 = Ct for
SLCO2B1 − Ct for ND1) and the ND5/SERPINA1 pair (∆Ct2 = Ct for SERPINA1 − Ct for ND5) were
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calculated, and the average of 2∆Ct for the values of ∆Ct1 and ∆Ct2 was used as a measure of relative
mtDNA abundance.
2.6. Statistical Analysis
The normal distribution of data was verified via the Kolmogorov–Smirnov test. Normally
distributed continuous variables were compared by one-way analysis of variance (ANOVA) followed
by Tukey’s post-hoc test when appropriate. Differences for non-normally distributed continuous
data were assessed by the non-parametric tests Mann–Whitney U and Kruskal–Wallis H with Dunns’
post-hoc test as appropriate. Differences in categorical variables among groups were determined via
χ2 statistics. Relationships between variables were explored by linear regression analysis and the
Pearson’s test. All analyses were performed using the GraphPrism 5.03 software (GraphPad Software,
Inc., San Diego, CA, USA), with statistical significance set at p < 0.05.
3. Results
3.1. Study Participants
Thirty-four participants, 11 young (six men and five women; median age: 22 years; interquartile
range: 21–28) and 23 older adults (14 men and nine women; median age: 80 years; interquartile range:
71–82) were included in the study. The main characteristics of study participants according to age
and SPPB categories were previously reported [32] and are shown in Table 2. Sex distribution, body
mass index, and the number of disease conditions and medications were comparable among groups.
Age did not differ between the two subgroups of older adults. Consistent with the study protocol,
HF participants had higher SPPB scores than LF older adults (p = 0.0002). Old participants showed a
greater abundance of muscle total Fe levels independent of the SPPB score (p = 0.0256).
Table 2. Characteristics of study participants according to age groups and physical
performance categories.
Young (n = 11) Old (n = 23)
Characteristic HF (n = 16) LF (n = 7) p Value
Age (years), median (IQR) 22 (21–28) 73 (71–81) * 80.0 (80–83) * <0.0001 a
Sex (women), n (%) 5 (45.5) 4 (25.0) 5 (71.4) 0.1076 b
BMI (kg/m2), mean ± SD 24.9 ± 4.2 27.7 ± 3.6 27.8 ± 4.2 0.1604 c
Total iron levels (ppm), median (IQR) 36.3 (32.9–58.8) 76.8 (54.0–111.3) * 82.9 (60.5–119.3) * 0.0256 c
Number of diseases ¥, median (IQR) 1.0 (0–2.0) 1.5 (1.0–3.0) 2 (1.0–4.0) 0.1274 c
Number of medications #, median (IQR) 1.5 (0–3.0) 3.0 (1.0–8.0) 3.0 (0.5–5.5) 0.3112 c
SPPB summary score, median (IQR) 11 (11–12) 6 (6–7) 0.0002 d
Abbreviations: BMI, body mass index; HF, high-functioning; IQR, interquartile range; LF, low-functioning; SD,
standard deviation; SPPB, short physical performance battery. * p < 0.05 vs. young group. ¥ includes hypertension,
coronary artery disease, prior stroke, peripheral vascular disease, diabetes, chronic obstructive pulmonary disease,
and osteoarthritis. # includes prescription and over-the-counter drugs. a Kruskal–Wallis H statistics. b χ2 test.
c One-way ANOVA. d Mann–Whitney U test.
3.2. Measurement of Mitochondrial Iron Handling Proteins and Quantification of Iron Isotopes in Muscle
Biopsies from Young and Old Participants
The expression of the two mitochondrial Fe handling proteins mitoferrin and frataxin were
measured in muscle samples and evaluated for their association with age and physical performance
categories. Mitoferrin levels were significantly higher in muscles of old LF participants compared with
young and HF groups (p < 0.05; Figure 1A). Conversely, lower protein levels of frataxin were observed
in LF older adults compared with young and HF participants (p < 0.05; Figure 1B).
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isotope fractionation. As expected, a value of 1.4848 was found for the slope of the linear trendline 
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leads to enrichment of the lighter isotope (54Fe) in the reduced fraction [20,21] and, according to 
Equation (1), lower abundance of δ56Fe and δ57Fe due to lower 56Fe/54Fe and 57Fe/54Fe relative to 
IRM014. As shown in Figure 2A, old LF participants showed lower abundance of δ56Fe compared 
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Comparison by one-way ANOVA of δ56Fe among young participants (n = 11) and high- (HF, n = 16) 
and low-functioning (LF, n = 7) older adults. (B) Linear regression analysis between δ57Fe and δ56Fe in 
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Figure 1. Protein levels of mitoferrin and frataxin in the vastus lateralis muscle of young and old
participants. (A) Comparisons of mitoferrin levels by Kruskal–Wallis H statistics and of (B) frataxin by
one-way ANOVA among young participants (n = 11) and high- (HF, n = 16) and low-functioning (LF,
n = 7) older adults. In (A) box plots represent median values (interquartile ranges), while in (B) bars
represent mean values (±standard deviation) for the three experimental groups. Values are expressed
in arbitrary units (a.u.) and representative blots are shown for each protein. * p < 0.05 vs. young group;
# p < 0.05 vs. HF group.
To gain insights into the Fe status of muscles, we measured the Fe isotope composition across
experimental groups. We then evaluated the relationship between δ56Fe and δ57Fe and between
δ56Fe and total Fe levels in the whole study population. The 56Fe/54Fe and 57Fe/54Fe ratios follow a
mass-dependent fractionation relationship (δ56Fe and δ57Fe; Figure 2B) indicating a mass-dependent
Fe isotope fractionation. As expected, a value of 1.4848 was found for the slope of the linear trendline
which is similar to the theoretical value of ln(57/54)/ln(56/54) ~ 1.487 [21]. The reduction of Fe3+ to
Fe2+ leads to enrichment of the lighter isotope (54Fe) in the reduced fraction [20,21] and, according
to Equation (1), lower abundance of δ56Fe and δ57Fe due to lower 56Fe/54Fe and 57Fe/54Fe relative to
IRM014. As shown in Figure 2A, old LF participants showed lower abundance of δ56Fe compared
with the young group (p = 0.0461). An inverse association was found between total Fe levels and
δ56Fe abundance in the whole study sample (Figure 2C). The linear correlation detected between more
negative δ56Fe and higher content of total Fe (Figure 2C) potentially indicates an increasing pool of
labile Fe in cells with Fe overload.
ll  , , x FOR PEER REVIEW 7 of 7 
 
 
  Protein levels of itoferrin and frataxin i  t e st s l t r lis scle f    
  i s of itofe rin levels by Kruskal–Wallis H s atistics and of (B) frataxin 
by one-way ANOVA among young participants (n = 11) and igh- (HF, n = 16) and low-functioning 
(LF, n = 7) older adults. In (A) box plots represent medi n values (inte qua tile ranges), while in (B) 
bars r present mean values (±standard deviation) fo  the th ee experimental groups. Values are 
exp essed in arbitrary u its (a.u.) and representative blots ar  s own for each protein. * p < 0.05 vs. 
young group; # p < 0.05 vs. HF group. 
To gain insights into the Fe status of uscles, e easured the Fe isotope co position across 
experi ental groups. We then evaluated the relationship between δ56Fe and δ57Fe and between δ56Fe 
and total Fe levels in the whole study population. The 56Fe/54Fe and 57Fe/54Fe ratios follow a mass-
dependent fractionation relationship (δ56Fe and δ57Fe; Figure 2B) indicating a mass-dependent Fe 
isotope fractionation. As expected, a value of 1.4848 was found for the slope of the linear trendline 
hich is si ilar to the theoretical value of ln(57/54)/ln(56/54) ~ 1.487 [21]. The reduction of Fe3+ to Fe2+ 
leads to enrichment of the lighter isotope (54Fe) in the reduced fraction [20,21] and, according to 
Equation (1), lower abundance of δ56Fe and δ57Fe due to lo er 56Fe/54Fe and 57Fe/54Fe relative to 
I 014. s sho n in Figure 2 , old LF participants sho ed lo er abundance of δ56Fe co pared 
ith the young group (p = 0.0461). An inverse association was found between total Fe levels and δ56Fe 
abundance in the whole study sample (Figure 2C). The linear correlation detected between ore 
negative δ56Fe and higher content of total Fe (Fig re 2 ) potentially in icates an increasing pool of 
labile Fe in cells ith Fe overloa . 
 
Figure 2. Iron isotope data for the vastus lateralis muscle of young and old participants. (A) 
Comparison by one-way ANOVA of δ56Fe among young participants (n = 11) and high- (HF, n = 16) 
and low-functioning (LF, n = 7) older adults. (B) Linear regression analysis between δ57Fe and δ56Fe in 
young and old participants. (C) Relationship between total Fe levels and δ56Fe in young and old 
participants as assessed by Pearson’s test. In (A) bars represent mean values (±standard deviation) for 
the three experimental groups. Values are expressed as ppm Fe. * p < 0.05 vs. young group. 
2. Iron isot pe data for the vastus lateralis muscle of young and old participants. (A) Comparison
by one-way ANOVA of δ56Fe among young participants (n = 11) and high- (HF, n = 16) and
low-functioning (LF, n = 7) older adults. (B) Linear l sis betw en δ57Fe and δ56Fe
in young and old participants. (C) Relationship between total Fe levels and δ56Fe in young a
( r sta ar i ti f
. . 0.05 s. young group.
Cells 2020, 9, 2579 8 of 16
3.3. Protein Levels of Selected Markers of Mitochondrial Quality Control and Abundance of the mtDNA4977
Common Deletion
As an indication of mitochondrial dynamics, we derived a fusion index from the ratio between
protein levels of the fusion marker optic atrophy 1 and those of the fission factor dynamin-related
protein 1 from previously published data in the same population [11]. The fusion index was lower in
old versus young participants independent of SPPB scores (Figure 3).
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Figure 3. Mitochondrial fusion index in the vastus lateralis muscle of young and old participants.
The fusion index was calculated as the ratio between protein levels of the fusion marker optic atrophy 1
(Opa1) and those of the fission factor dyna in-related protein 1 (Drp1). Differences a ong groups
were assessed by one-way ANOVA. Bars represent mean values (±standard deviation) for the three
experimental groups. * p < 0.05 vs. young group (n = 11); HF: high-functioning (n = 16); LF:
low-functioning (n = 7).
Selected markers of general (i.e., beclin, LC3B, and p62) and mitochondrial autophagy (i.e., Pink1
and Parkin) were measured in muscle biopsies of all participants and related with age and physical
performance. No differences among groups were found for the protein content of beclin (p = 0.5446,
Figure 4A). However, the ratio between the lipidated (II) and the non-lipidated form (I) of LC3B and
protein levels of p62, two markers of autophagic flux [64], were significantly lower in old participants
independent of SPPB categories (p < 0.05, Figure 4B,C).
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Figure 4. Selected markers of general autophagy in the vastus lateralis uscle of young and old
participan o pa i on by one-way ANOVA of (A) protein levels of beclin, (B) ratio between lipidated
(II) and non-lipidated (I) microtubule-associated protein 1A/1B-l ght chain 3 (LC3B), and (C) protein
levels of p62 among young participants (n = 11) and high- (HF, n = 16) and low-functioning (LF, n = 7)
older adults. Bars represent mean values (±standard deviation) for the three experimental groups.
Values are expressed in arbitrary units (a.u.) and representative blots are shown for each protein.
* p < 0.05 vs. young group.
Cells 2020, 9, 2579 9 of 16
As for the mitophagy markers assayed, higher protein levels of Pink1 were detected in old LF
participants compared with young and HF participants (p < 0.05, Figure 5A). Protein levels of Parkin
were instead unvaried among groups (p = 0.6338, Figure 5B).
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The maintenance of skeletal muscle homeostasis relies upon the fine tuning of several processes, 
including ion balance [65–67]. Indeed, Fe dyshomeostasis is invoked as a factor contributing to age-
associated muscle atrophy in rodents and humans through the mediation of oxidative stress [31,32]. 
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Figure 5. Protein levels of selected markers of mitophagy in the vastus lateralis muscle of young and old
participants. Comparison by one-way ANOVA of ( ) phosphatase and tensin homolog-induced kinase
1 (Pink1) and (B) Parkin among young participants (n = 11) and high- (HF, n = 16) and low-functioning
(LF, n = 7) older adults. Bars represent mean values (± standard deviation) for the three experimental
groups. Values are expressed in arbitrary units (a.u.) and representative blots are shown for each
protein. * p < 0.05 vs. young group. # p < 0.05 vs. HF group.
Finally, the relative abundance of the mtDNA common deletion (mtDNA4977) was quantified as
a marker of mitochondrial damage. The abundance of such deletion was greater in old participants
compared with the young group irrespective of the SPPB category (p < 0.05, Figure 6).
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4. Discussion
The mai tenance of skeletal muscle homeostasis relies upon the fine tuning of several processes,
including ion balance [65–67]. Indeed, Fe dyshomeostasis is invoked as a factor contributing to
age-associated muscle atrophy in rodents and humans through the mediation of oxidative stress [31,32].
A previous study by our group reported higher levels of non-heme Fe in muscles of old rats
following hind limb suspension [31]. In rodent muscles, Fe overload was also shown to occur
during aging and to be associated with RNA oxidative damage in subsarcolemmal mitochondria [33].
More recently, the relationship between muscular Fe status and age was also investigated in humans [32].
An age-dependent accumulation of non-heme Fe in muscle was found, which was associated with
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lower mtDNA content and greater mtDNA oxidative damage [32]. However, whether non-heme
Fe accumulation in muscle with age is associated with excess labile Fe, as well as its relationship
with changes in the expression of proteins involved in mitochondrial Fe handling and quality control,
has remained unexplored. Hence, we sought to tackle this aspect of muscle Fe status by investigating
whether the Fe isotope composition would be linked to MQC alterations during aging. We also
explored whether labile Fe in muscle would be associated with physical performance.
In humans, the relative abundance of Fe isotopes (i.e., isotope fractionation) depends on redox
conditions more than on ligand coordination [21], therefore reflecting the redox status of the surrounding
milieu. In the scenario, an enrichment in Fe2+ is characterized by lower abundance of δ56Fe and
δ57Fe [21]. Hence, old LF participants, in whom more negative levels of δ56Fe were observed, likely
had higher levels of Fe2+ in muscle (Figure 2A). This finding, together with the observation of a higher
expression of the mitochondrial Fe transporter mitoferrin and a lower content of the mitochondrial Fe
storage protein frataxin in the same participant group (Figure 1A,B), suggests a possible dysregulation
of mitochondrial Fe handling [68]. This idea is in keeping with the recent observation of increased
intracellular labile Fe in conjunction with upregulation of mitoferrin in a mouse model of frataxin
deficiency [68]. Mitoferrin upregulation in muscles of LF older adults might therefore be interpreted
as a cell’s response to buffer Fe excess. This hypothesis is supported by the lower levels of frataxin
detected in the same group, which might be indicative of inability of mitochondria to cope with Fe
overload. This, in turn, would overwhelm the mitochondrial Fe storage capacity with most of the
metal remaining unbound. The increased labile Fe content within mitochondria may compromise the
organellar integrity via Fenton chemistry, as reflected by the greater abundance of mtDNA4977 deletion
in old participants (Figure 6).
A shift of mitochondrial dynamics toward fusion is thought to serve as a mechanism to
dilute mtDNA damage, including mtDNA4977 deletion, along the network, thereby avoiding its
focal accumulation [38]. However, the fusion index, a surrogate indicator of the balance between
mitochondrial fusion and fission, was lower in old compared with young participants (Figure 3).
This finding could reflect the exhaustion of this compensatory mechanism in the aged muscle.
Alternatively, a lower fusion index may indicate a shift toward fission as a response to extensive
mitochondrial damage [38,69]. This idea is supported by the lower expression of frataxin in old
LF participants which might represent an Fe-induced mitochondrial stress response to trigger
Pink1/Parkin-dependent mitophagy for the disposal of damaged organelles [70]. However, this
was not accompanied by an upregulation of the mitophagic flux, as suggested by decreased LC3B II/I
(Figure 4B) and lower p62 levels (Figure 4C) in old participants. Collectively, these findings suggest
that the clearance of damaged mitochondria via this route could not be achieved. Indeed, mitochondria
primed for mitophagy by Pink1 might not be processed further as a consequence of possible clogging of
this degradative pathway, as reflected by unvaried Parkin expression (Figure 5). Based on findings from
the present study and those reported previously in the same participant cohort [32], an integrated set of
molecular events linking age-related systemic and muscular Fe dyshomeostasis, MQC derangements,
and systemic inflammation may be hypothesized as depicted in Figure 7.
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Figure 7. Schematic representation of putative pathways linking age-related systemic and muscular
iron dyshomeostasis, derangements in mitochondrial quality control, and systemic inflammation.
Red callouts indicate mediators/processes that are mainly dysregulated. Abbreviations: DAMPs,
damage-associated molecular patterns; Dcytb2, duodenal cytochrome b2; DMT1, divalent metal
transporter 1; Fpn, ferroportin; IRP1/2, iron-responsive element-binding protein 1/2; PARL,
presenilin-associated rhomboid-like protein; Pink1, phosphatase and tensin homolog-induced kinase
1; ROS, reactive oxygen species; SDR2, stromal cell-derived receptor 2; STEAP2, six-transmembrane
epithelial antigen of the prostate 2; Tf, transferrin; TfR, transferrin receptor; TIM23, translocase of
inner mitochondrial membrane 23; TOM, translocase of the outer mitochondrial membrane; ZIP14,
Zrt-Irt-like protein 14.
The possibility that Fe mishandling in skeletal muscle might impact physical function through
interfering with mitochondrial homeostasis and quality control opens new venues for interventions.
Indeed, pharmacological compounds that are already in clinical use to treat a variety of Fe overload
diseases (e.g., desferoxamine, deferasirox, deferiprone, salicylaldehyde isonicotinoyl hydrazone,
alpha-lipoic acid) may be tested for their ability to scavenge and remove Fe from muscles. Such an
approach is currently being explored to treat neurodegenerative diseases characterized by focal Fe
accumulation, including Alzheimer’s disease, Parkinson’s disease, Friedreich’s ataxia, and amyotrophic
lateral sclerosis [71]. An important issue related to Fe chelation therapy is that presently available
compounds are not selective for organs or macromolecular structures. This may substantially limit
their use in older adults, in whom iron-deficient anemia is highly prevalent [72]. Calorie restriction
(CR) has been shown to mitigate age-associated Fe accumulation in various rodent tissues, including
muscle [30]. However, the long-term implementation of this dietary regimen is hampered by feasibility
and tolerability issues, especially in frail older adults [73]. This limitation may be overcome through
the use of CR mimetics [73], among which resveratrol was found to attenuate the detrimental effects of
Fe overload in preclinical models [74,75]. Whatever the strategy used, the perspective of preserving
physical function in old age via ameliorating muscle Fe handling and mitochondrial homeostasis
is worth exploration. In particular, studies are warranted to (1) definitely establish the role of Fe
dysmetabolism in muscle aging and physical function decline, (2) determine the optimal timing for Fe
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scavenging therapies, and (3) identify noninvasively accessible markers of muscle Fe status to monitor
the intervention.
5. Limitations
To our knowledge, this is the first study to investigate Fe isotope composition and the expression
of mitochondrial Fe handling proteins, mitoferrin and frataxin, in human skeletal muscle. However,
our work has some limitations that deserve discussion. First of all, the small sample size makes the study
exploratory in nature and did not allow analyses to be adjusted for sex or other possible confounders.
The limited amount of muscle tissue available narrowed our analyses to selected mediators of pathways
pertaining to Fe handling and MQC mechanisms. Indeed, total and phosphorylated protein levels
of other mitophagy-related factors, such as TANK-binding kinase 1, optineurin, nuclear dot protein
52, and ubiquitin could not be assessed, which prevented us from achieving a more comprehensive
appraisal of the mitophagic process. The cross-sectional design of the study does not allow inferences
to be made about the time course of changes of the analyzed factors and cause-effect relationships.
For the same reason, no mechanistic hypotheses could be tested regarding the processes leading to
Fe dyshomeostasis in muscle and its impact on mitochondrial health. Indeed, our data do not allow
establishing whether Fe reduction and isotope fractionation occurred as a result of intracellular redox
reactions or during Fe import within the cell. In the latter scenario, since the expression of TfR1 was
previously found to be substantially downregulated in muscles of old LF participants [32], Fe isotope
fractionation might have occurred during Fe import via divalent metal transporter 1 or Zrt-Irt-like
protein 14. This point warrants further exploration through ad hoc designed investigations. Finally,
the study did not include actively exercising participants. Although a physically inactive lifestyle
was one of the eligibility criteria, this information was collected through self-report and no objective
measure of physical activity was obtained. The lack of this information impeded the appreciation of
possible effects of exercise or physical activity on Fe status, mtDNA4977 abundance, and the expression
of MQC mediators in muscle.
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